Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Arsene-Bienvenu Loembé"'
Autor:
Elizabeth L. Hardaker, Emilio Sanseviero, Ankur Karmokar, Devon Taylor, Marta Milo, Chrysis Michaloglou, Adina Hughes, Mimi Mai, Matthew King, Anisha Solanki, Lukasz Magiera, Ricardo Miragaia, Gozde Kar, Nathan Standifer, Michael Surace, Shaan Gill, Alison Peter, Sara Talbot, Sehmus Tohumeken, Henderson Fryer, Ali Mostafa, Kathy Mulgrew, Carolyn Lam, Scott Hoffmann, Daniel Sutton, Larissa Carnevalli, Fernando J. Calero-Nieto, Gemma N. Jones, Andrew J. Pierce, Zena Wilson, David Campbell, Lynet Nyoni, Carla P. Martins, Tamara Baker, Gilberto Serrano de Almeida, Zainab Ramlaoui, Abdel Bidar, Benjamin Phillips, Joseph Boland, Sonia Iyer, J. Carl Barrett, Arsene-Bienvenu Loembé, Serge Y. Fuchs, Umamaheswar Duvvuri, Pei-Jen Lou, Melonie A. Nance, Carlos Alberto Gomez Roca, Elaine Cadogan, Susan E. Critichlow, Steven Fawell, Mark Cobbold, Emma Dean, Viia Valge-Archer, Alan Lau, Dmitry I. Gabrilovich, Simon T. Barry
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-20 (2024)
Abstract The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we
Externí odkaz:
https://doaj.org/article/189773f2417346dcbdf8b6281d57effa
Autor:
Simon Smith, Woong-Yang Park, Kyoung-Mee Kim, Jeeyun Lee, Jung Yong Hong, Seung Tae Kim, Won Ki Kang, Emma Dean, Minsuk Kwon, Gahyun Kim, Ryul Kim, Kyu-Tae Kim, Peter G S Mortimer, Arsene-Bienvenu Loembé, Itziar Irurzun-Arana, Loumpiana Koulai
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Targeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which is a master regulator o
Externí odkaz:
https://doaj.org/article/0fb079375db848879a747baa38eb0c19
Autor:
Jeeyun Lee, Emma Dean, Andrew J. Pierce, Iwanka Kozarewa, Won Ki Kang, Ho Yeong Lim, Young Suk Park, Joon Oh Park, Se Hoon Park, Jung Yong Hong, Alienor Berges, Itziar Irurzun-Arana, Sophie Willis, Claire Smith, Kyoung-Mee Kim, Heejin Cho, Arsene-Bienvenu Loembé, Peter Mortimer, Simon A. Smith, Seung Tae Kim
Purpose:Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein.Patients and Methods:Eligible patients with solid tumors, enriched for melanoma, received cerala
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bc7339c2ee702e3eb8aed960329ad70
https://doi.org/10.1158/1078-0432.c.6530478
https://doi.org/10.1158/1078-0432.c.6530478
Autor:
Jeeyun Lee, Emma Dean, Andrew J. Pierce, Iwanka Kozarewa, Won Ki Kang, Ho Yeong Lim, Young Suk Park, Joon Oh Park, Se Hoon Park, Jung Yong Hong, Alienor Berges, Itziar Irurzun-Arana, Sophie Willis, Claire Smith, Kyoung-Mee Kim, Heejin Cho, Arsene-Bienvenu Loembé, Peter Mortimer, Simon A. Smith, Seung Tae Kim
Supplementary Table 1. Treatment Outcomes for individual trial participants and dose cohort (N=57)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66b409678377e7ddd68c3f898aa966dc
https://doi.org/10.1158/1078-0432.22480593
https://doi.org/10.1158/1078-0432.22480593
Autor:
Jeeyun Lee, Emma Dean, Andrew J. Pierce, Iwanka Kozarewa, Won Ki Kang, Ho Yeong Lim, Young Suk Park, Joon Oh Park, Se Hoon Park, Jung Yong Hong, Alienor Berges, Itziar Irurzun-Arana, Sophie Willis, Claire Smith, Kyoung-Mee Kim, Heejin Cho, Arsene-Bienvenu Loembé, Peter Mortimer, Simon A. Smith, Seung Tae Kim
Supplementary Figure 1. Single dose ceralasertib PK. PK from patients in cohorts 1 to 4 was in line with the PK model predictions (shadowed area) built with data from other studies. Supplementary Figure 2. ATM protein expression by IHC in patients wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58c11c29c87f565265f18dfa184a1c2f
https://doi.org/10.1158/1078-0432.22480596.v1
https://doi.org/10.1158/1078-0432.22480596.v1
Autor:
Young Suk Park, Peter G. Mortimer, Kyoung-Mee Kim, Sophie E. Willis, Emma Dean, Claire Smith, Jung Yong Hong, Itziar Irurzun-Arana, Arsene-Bienvenu Loembé, Joon Oh Park, Iwanka Kozarewa, Andrew J. Pierce, Jeeyun Lee, Ho Yeong Lim, Simon Smith, Alienor Berges, Won Ki Kang, Hee Jin Cho, Seung Tae Kim, Se Hoon Park
Publikováno v:
Clinical Cancer Research. 27:4700-4709
Purpose: Ceralasertib is a potent and selective oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related (ATR) protein. Patients and Methods: Eligible patients with solid tumors, enriched for melanoma, received cer
Autor:
Minsuk Kwon, Gahyun Kim, Ryul Kim, Kyu-Tae Kim, Seung Tae Kim, Simon Smith, Peter G S Mortimer, Jung Yong Hong, Arsene-Bienvenu Loembé, Itziar Irurzun-Arana, Loumpiana Koulai, Kyoung-Mee Kim, Won Ki Kang, Emma Dean, Woong-Yang Park, Jeeyun Lee
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e005041
BackgroundTargeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which is a master regulator of